uPAR/PLAUR Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

PLAUR (Plasminogen Activator, Urokinase Receptor) is a protein coding gene located on human chromosome 19q13.31. PLAUR is also known as CD87, UPAR, URKR and U-PAR. The human PLAUR gene encodes a 36978 Da protein containing 335 amino acids. The PLAUR protein is biasedly expressed in bone marrow, gall bladder and other tissues. Among its related pathways are Post-translational modification- synthesis of GPI-anchored proteins and amb2 Integrin signaling. PLAUR is related to signaling receptor binding. LYPD3 is an important paralog of PLAUR gene. PLAUR is associated with some diseases, including Ureter, Cancer Of and Paroxysmal Nocturnal Hemoglobinuria.

uPAR/PLAUR Protein (3)

    uPAR/PLAUR Antibody (19)

      uPAR/PLAUR ELISA Kit & Match Antibody ELISA Pair Set (2)

      uPAR/PLAUR cDNA Clone (26)

      NM_002659.2
      NM_011113.3

      uPAR/PLAUR Lysate (3)

        uPAR/PLAUR Background

        Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.

        uPAR/PLAUR References

        • Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
        • Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
        • Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
        • Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.